Equities

Ocean Biomedical Inc

Ocean Biomedical Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.40
  • Today's Change-0.075 / -5.10%
  • Shares traded137.23k
  • 1 Year change-78.10%
  • Beta--
Data delayed at least 15 minutes, as of May 06 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ocean Biomedical Holdings, Inc., formerly Ocean Biomedical, Inc., is a United States-based biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases and inflammation. In oncology, it is developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). In fibrosis, it is developing a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS). It has three product candidates: a malaria vaccine candidate targeting either or both of Plasmodium falciparum schizont egress antigen (PfSEA-1), and parasite antigen Plasmodium falciparum glutamic-acid-rich protein(PfGARP); a humanized mAb malaria therapeutic candidate targeting PfGARP; and a small molecule malaria therapeutic candidate.

  • Revenue in USD (TTM)0.00
  • Net income in USD-98.59m
  • Incorporated2021
  • Employees9.00
  • Location
    Ocean Biomedical Inc55 Claverick Street, Room 212PROVIDENCE 02903United StatesUSA
  • Phone+1 (401) 444-7375
  • Fax+1 (302) 655-5049
  • Websitehttps://www.oceanbiomedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Medicine Man Technologies Inc172.45m-42.70m48.52m729.00--0.3845--0.2814-1.60-1.603.011.610.50643.9939.49236,553.90-10.15-8.33-11.95-9.8544.0845.57-20.03-15.710.50270.31430.5679--8.2078.78-62.56--200.89--
Immuneering Corp0.00-53.47m48.63m68.00--0.530-----1.89-1.890.003.090.00----0.00-47.54---51.16--------------0.00---100.00---5.86------
Ocuphire Pharma Inc19.05m-9.99m49.38m14.00--0.9561--2.59-0.4735-0.47350.87272.080.3701--5.301,360,643.00-19.40-58.31-20.77-65.94-----52.42-137.92---8.460.00---52.20---155.83------
Modular Medical Inc0.00-16.76m49.89m37.00--8.92-----0.9653-0.96530.000.18050.00----0.00-224.40-168.16-262.22-209.51------------0.00------25.51--154.53--
Odonate Inc0.00-102.07m50.02m137.00--1,844.41-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
Correlate Energy Corp7.56m-12.79m50.15m19.00------6.63-0.3554-0.35540.21-0.08772.22--13.19398,051.60-375.16-315.47----18.2715.42-169.09-201.03---0.72398.30--122.2046.12-78.54------
Hcw Biologics Inc2.84m-24.99m50.31m45.00--3.56--17.70-0.6953-0.69530.07910.37370.0755--2.9163,150.89-66.37---78.58--19.72---879.53-----90.860.319---57.72---67.74------
Ocean Biomedical Holdings Inc0.00-45.58m50.93m9.00---------1.40-1.400.00-0.0642------0.00-----------------------------612.50------
Journey Medical Corp79.18m-3.85m51.41m58.00--3.50--0.6493-0.3502-0.35024.191.050.87012.193.651,365,190.00-4.23---10.51--66.33---4.87--1.100.68630.4641--7.48--87.00------
Eyenovia Inc3.79k-27.26m51.47m57.00--5.11--13,579.80-0.6639-0.66390.000090.19760.0001--0.003166.49-91.15-80.31-119.11-117.700.00---719,290.30-680.952.16-15.140.6135------2.68--152.20--
Aadi Bioscience Inc24.35m-65.77m52.05m74.00--0.4948--2.14-2.44-2.440.90494.280.15380.67796.63273,640.40-41.54-50.25-48.46-56.1588.47---270.04-473.974.48--0.00--60.063.85-8.68--153.54--
Intensity Therapeutics Inc0.00-11.86m52.92m5.00--4.02-----0.8653-0.86530.000.96010.00----0.00-110.62---254.70--------------0.00-------56.45------
Enzo Biochem Inc32.80m-23.31m53.27m179.00--0.7419--1.62-0.46990.67080.65861.400.37381.614.10183,257.00-26.56-12.21-39.50-15.7942.1737.09-71.07-18.762.89--0.0476---4.85-21.01-23.02--7.89--
Data as of May 06 2024. Currency figures normalised to Ocean Biomedical Inc's reporting currency: US Dollar USD

Institutional shareholders

12.55%Per cent of shares held by top holders
HolderShares% Held
Polar Asset Management Partners, Inc.as of 31 Dec 20232.69m7.89%
Meteora Capital LLCas of 31 Dec 2023568.40k1.67%
BlackRock Fund Advisorsas of 31 Dec 2023248.58k0.73%
Geode Capital Management LLCas of 31 Dec 2023239.07k0.70%
The Vanguard Group, Inc.as of 31 Dec 2023147.96k0.43%
SSgA Funds Management, Inc.as of 31 Dec 2023136.31k0.40%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 202384.55k0.25%
Cohen & Company Financial Management LLCas of 30 Sep 202359.72k0.18%
AllianceBernstein LPas of 31 Dec 202355.08k0.16%
Morgan Stanley & Co. LLCas of 31 Dec 202347.94k0.14%
More ▼
Data from 30 Sep 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.